Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
- Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease
Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB). These include Dr Samantha Budd Haeberlein, PhD, Henrik Zetterberg, MD, PhD, Rik Ossenkoppele, PhD, and Christopher van Dyck, MD.
